Employer coverage of GLP-1s for weight loss: the IFEBP 2026 survey numbers

Most working-age Americans get drug coverage through an employer, so the employer decision is the one that decides whether a Wegovy or Zepbound prescription costs $25 or $349 a month. The best recurring measure of that decision is the International Foundation of Employee Benefit Plans' annual pulse survey. The 2026 edition, fielded in June 2026 on almost 300 U.S. employer health plans and released in July, is summarised here with the previous three years.

The headline numbers, corporate employers

Source: IFEBP Word on Benefits summary of the 2026 pulse survey and prior editions. Weight-loss coverage doubled between 2023 and 2025 and then stopped; 2026 is flat on 2025. Diabetes-only coverage rose five points, which reads as some plans holding the line on diabetes while declining to add obesity. The 45 percent covering other approved conditions (cardiovascular risk reduction with Wegovy, sleep apneaobstructive sleep apneaRepeated blocking of the airway during sleep; Zepbound has a label indication for it in adults with obesity. with Zepbound) is new to the 2026 survey and sits between the two.

Multiemployer and public-sector plans lag: 31 percent cover both diabetes and weight loss.

How plans that cover manage it

Among plans covering GLP-1s for weight loss, the 2026 survey reports the eligibility requirements most commonly used:

Prior authorizationprior authorizationApproval an insurer requires before it will pay for a medicine. is the mechanism behind all three. In practice the label thresholds (BMI 30, or 27 with a weight-related condition) are the floor and many plans set the bar higher; the survey does not report the distribution of BMI thresholds.

Cost pressure

GLP-1 drugs for weight loss represented 6.9 percent of annual claims for corporate respondents in 2023 and 11.4 percent in 2025; for multiemployer and public plans, 14.7 percent. That is the number behind the plateau. A plan whose largest single drug category doubled its share in two years is not looking for reasons to widen eligibility, and the survey coverage in the trade and business press in July and August 2026 was framed around plans steering employees to cash channels rather than adding coverage.

What this means for what you pay

• If your plan is in the 36 percent: the manufacturer card takes a covered copay to as little as $25 within the caps on the savings-card page.
• If your plan is in the diabetes-only 60 percent: Wegovy and Zepbound are excluded, the card does nothing, and the self-payself-payPaying the full price yourself, without insurance. routes (LillyDirect, NovoCare, TrumpRx) at $199 to $449 a month are what remain. Some employers now arrange access to those cash prices through a vendor rather than covering the drug; the price is the same, the arrangement is administrative.
• If your plan covers with a BMI or comorbidity requirement you do not meet: the plan's appeal process exists, and the prescriber's documentation decides it. Denials on a label indication other than weight loss (cardiovascular risk, sleep apnea) are worth appealing because 45 percent of plans cover those indications separately.
• If your plan sits with a copay accumulator or maximizer program: card payments may not count toward your deductible; ask before relying on the annual cap.

Sources and dates

The IFEBP survey page and the Word on Benefits summary carry the 2026 figures and the 2023 to 2025 comparisons; CNBC's July 8, 2026 report gives the fielding month and sample size. Figures here are quoted as published and were read on September 4, 2026. The 2027 edition, if IFEBP keeps the cadence, would land in July 2027 and this page will be updated with it.